Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature Medicine 9, 944 - 951 (2003)
Published online: 15 June 2003 | doi:10.1038/nm891
There is an Erratum (September 2003) associated with this Article.
Deletion of cytosolic phospholipase A2 promotes striated muscle growth
Syed Haq1,7, Heiko Kilter1,7, Ashour Michael1,7, Jingzang Tao2, Eileen O'Leary2, Xio Ming Sun2, Brian Walters1, Kausik Bhattacharya1, Xin Chen1, Lei Cui3, Michele Andreucci2,6, Anthony Rosenzweig2, J. Luis Guerrero2, Richard Patten1, Ronglih Liao3, Jeffery Molkentin4, Michael Picard2, Joseph V. Bonventre5 & Thomas Force1
Abstract
Generation of arachidonic acid by the ubiquitously expressed cytosolic phospholipase A2 (PLA2) has a fundamental role in the regulation of cellular homeostasis, inflammation and tumorigenesis. Here we report that cytosolic PLA2 is a negative regulator of growth, specifically of striated muscle. We find that normal growth of skeletal muscle, as well as normal and pathologic stress-induced hypertrophic growth of the heart, are exaggerated in Pla2g4a-/- mice, which lack the gene encoding cytosolic PLA2. The mechanism underlying this phenotype is that cytosolic PLA2 negatively regulates insulin-like growth factor (IGF)-1 signaling. Absence of cytosolic PLA2 leads to sustained activation of the IGF-1 pathway, which results from the failure of 3-phosphoinositide-dependent protein kinase (PDK)-1 to recruit and phosphorylate protein kinase C (PKC)-
, a negative regulator of IGF-1 signaling. Arachidonic acid restores activation of PKC-
, correcting the exaggerated IGF-1 signaling. These results indicate that cytosolic PLA2 and arachidonic acid regulate striated muscle growth by modulating multiple growth-regulatory pathways.
To read this story in full you will need to login or make a payment (see right).
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE REVIEWS RESEARCH |

B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications